Literature DB >> 18607893

Reconstruction of full-thickness nasal defect by free anterolateral thigh flap.

Murat Livaoğlu1, Naci Karacal, Devrim Bektaş, Osman Bahadir.   

Abstract

CONCLUSION: Because of minimal donor region morbidity, pliability, the presence of long and large caliber vessels, and lack of visible scar, the free anterolateral thigh flap provides an ideal option for restoration of full-thickness nasal defects.
OBJECTIVE: Full-thickness nasal defect reconstruction requires internal nasal lining and external cover. In large defects, internal nasal lining replacement with traditional sources may not be expedient. We describe reconstruction of full-thickness nasal defects with free anterolateral thigh flap. PATIENTS AND METHODS: From August 2005 to July 2007, six patients with full-thickness nasal defects underwent nasal reconstruction using free anterolateral thigh flap. All defects resulted from tumor resections. Four patients had a basal cell carcinoma, one an epidermoid carcinoma, and the other patient had recurrent malignant fibrous histiocytoma.
RESULTS: All flaps survived completely. The average hospitalization time was 3 days. No complication was observed.

Entities:  

Mesh:

Year:  2009        PMID: 18607893     DOI: 10.1080/00016480802258810

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  2 in total

1.  Outcomes Associated with Nasal Reconstruction Post-Rhinectomy: A Narrative Review.

Authors:  Jithin John; Rohun Gupta; Anne Grossbauer; Michael Chung; Anita Sethna; Michel Abboud; Eric Cox; Justin Hart; Adam Folbe; Kongkrit Chaiyasate
Journal:  Arch Plast Surg       Date:  2022-04-06

Review 2.  Interdisciplinary challenges and aims of flap or graft reconstruction surgery of sinonasal cancers: What radiologists and radiation oncologists need to know.

Authors:  Florent Carsuzaa; Benjamin Verillaud; Pierre-Yves Marcy; Philippe Herman; Xavier Dufour; Valentin Favier; Juliette Thariat
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.